Session

24.03.2021     08:00–19:30

Title:
ePoster self study
Antivirals & Resistance
Type:
ePoster self study

24.03.2021
08:00–19:30

Title:
ePoster self study
Antivirals & Resistance
Type:
ePoster self study

P 12 Diazadispiroalkane derivatives – new viral entry inhibitors
Elke Bogner (Berlin/DE)


P 13 Targeting the endolysosomal host-SARS-CoV-2 interface by clinically licensed functional inhibitors of acid sphingomyelinase (FIASMA) including the antidepressant fluoxetine and the drug synergy of combinatory treatment with remdesivir
Sebastian Schloer (Münster/DE)


P 14 A neuraminidase inhibitor, DANA, inhibited Shaan virus replication in MARC145 cell
Seong Sik Jang (Cheongju/KR)


P 15 Towards the next epizootic disease eradication - a novel recombinant Newcastle disease virus vectored DIVA vaccine against peste des petits ruminants in goats
Magdalena Murr (Greifswald-Insel Riems/DE)


P 16 Defective interfering particles as antivirals - production, purification and animal testing
Marc D. Hein (Magdeburg/DE)


P 18 Immunotherapy with interferon α, but not interferon beta, controlled persistent retroviral infection
Kathrin Sutter (Essen/DE)


P 19 Establishment of a production system for influenza A virus-derived defective interfering particles (DIPs) harboring multiple DI RNAs
Najat Bdeir (Göttingen/DE)


P 20 Targeting translation - natural compounds and their derivates against SARS-CoV-2
Saskia Weber (Greifswald-Insel Riems/DE)


P 21 Systematic analysis of RNAi-accessible SARS-CoV-2 replication steps
Shubhankar Ambike (München/DE), Thomas Michler (München/DE)


P 23 Novel eIF4A-specific RNA helicase inhibitors as potential broad-spectrum antivirals
Wiebke Obermann (Marburg/DE)


P 24 Inhibitors of protein glycosylation are active against the human Severe Acute Respiratory Syndrome Coronavirus SARS-CoV2
Rafaela Milan Bonotto (Trieste/IT)


P 26 IMU-838, a developmental DHODH inhibitor in phase II for autoimmune disease, shows anti-SARS-CoV-2 and broad-spectrum antiviral efficacy in vitro
Friedrich Hahn (Erlangen/DE)


P 27 Adjuvant formulated virus-like particles expressing native-like forms of the Lassa virus envelope surface glycoprotein are immunogenic and induce antibodies with broadly neutralizing activity
Helena Mueller-Kraeuter (Marburg/DE)


P 28 Impact of latency reversing agents on transactivation of the HTLV-1 promoter
Annika P. Schnell (Erlangen/DE)


P 29 Cullin ubiquitin ligases constitute druggable Achilles' Heels of retroviruses
Kevin Thomas Pattberg (Essen/DE)


P 30 ATO (Arsenic Trioxide) effects on PML nuclear bodies reveals antiviral intervention capacity    
Sabrina Schreiner (Hannover/DE)


P 31 Exploring the bromodomain and extra-terminal (BET) inhibitor JQ-1 as a potential inhibitor of SARS-CoV-2 infection
Baxolele Mhlekude (Berlin/DE)


P 32 Two-drug regimen (2DR) for initial HIV treatment? – Lessons learned from 20 years RESINA cohort  
Nadine Lübke (Düsseldorf/DE)


P 33 A cell-based luciferase assay for high-throughput screening of SARS-CoV2 3CLpro (Nsp5) inhibitors
Tim Krischuns (Paris/FR)


P 34 Cullin RING ubiquitin ligases are host factors and drug targets for herpesviruses
Yulia Flores-Martinez (Duisburg/DE)


P 35 Compounds present in universally available herbal teas based on sage and perilla elicit potent antiviral activity against SARS-CoV-2 in vitro
Vu Thuy Khanh Le-Trilling (Essen/DE)